Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription 15.02.2021 2 Ann Oncol 3 Ann Thorac Surg 2 Anticancer Res 1 Arch Bronconeumol 7 BMC Cancer 1 Cancer Cell 11 Cancer Res 1 Cancer Sci 1 Carcinogenesis 4 Chest 3 Clin Cancer Res 5 Clin Lung Cancer 1 Eur Respir J 1 Genes Chromosomes Cancer 1 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Immunol 6 J Thorac Cardiovasc Surg 3 J Thorac Oncol 2 JAMA Oncol 1 Lancet Oncol 4 Lung Cancer 2 Mol Cancer Ther 3 N Engl J Med 2 Oncogene 1 Oncol Rep 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. SUBBIAH V, Shen T, Terzyan SS, Liu X, et al
   Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
   Ann Oncol. 2021;32:261-268.
   PubMed         Abstract available
   
   
2. SATURNO G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, et al
   The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
   Ann Oncol. 2021;32:269-278.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

3. SHIPE ME, Deppen SA, Sullivan S, Kammer M, et al
   Validation of Histoplasmosis Enzyme Immunoassay to Evaluate Suspicious Lung Nodules.
   Ann Thorac Surg. 2021;111:416-420.
   PubMed         Abstract available
   
   
4. TOWE CW, Worrell SG, Bachman K, Sarode AL, et al
   Neoadjuvant Treatment Is Associated With Superior Outcomes in T4 Lung Cancers With Local Extension.
   Ann Thorac Surg. 2021;111:448-455.
   PubMed         Abstract available
   
   
5. LEE SY, Jeon JH, Jung W, Chae M, et al
   Predictive Factors for Lymph Node Metastasis in Clinical Stage I Part-Solid Lung Adenocarcinoma.
   Ann Thorac Surg. 2021;111:456-462.
   PubMed         Abstract available
   
   

   
   Anticancer Res

6. YAMASHITA N, Oyama T, So T, Miyata T, et al
   Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma.
   Anticancer Res. 2021;41:905-910.
   PubMed         Abstract available
   
   
7. OSHIRO H, Tome Y, Miyake K, Higuchi T, et al
   A Novel Orthotopic Mouse Model of Lung Metastasis Using Fluorescent Patient-derived Osteosarcoma Cells.
   Anticancer Res. 2021;41:635-640.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

8. CORBACHO ABELAIRA MD, Ruano-Ravina A, Fernandez-Villar A
   Artificial Intelligence in Thoracic Radiology. A Challenge in COVID-19 Times?
   Arch Bronconeumol. 2021;57 Suppl 1:15-16.
   PubMed        
   
   

   
   BMC Cancer

9. PAZIK M, Michalska K, Zebrowska-Nawrocka M, Zawadzka I, et al
   Clinical significance of HRAS and KRAS genes expression in patients with non-small-cell lung cancer - preliminary findings.
   BMC Cancer. 2021;21:130.
   PubMed         Abstract available
   
   
10. KIDD J, Cassim S, Rolleston A, Chepulis L, et al
    Ha Ora: secondary care barriers and enablers to early diagnosis of lung cancer for Maori communities.
    BMC Cancer. 2021;21:121.
    PubMed         Abstract available
    
    
11. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed         Abstract available
    
    
12. WU X, Zhang X, Tao L, Chen P, et al
    Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).
    BMC Cancer. 2020;20:719.
    PubMed         Abstract available
    
    
13. JIA M, Yu S, Yu J, Li Y, et al
    Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.
    BMC Cancer. 2020;20:705.
    PubMed         Abstract available
    
    
14. CHEN Y, Hu J, Bu F, Zhang H, et al
    Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:707.
    PubMed         Abstract available
    
    
15. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed         Abstract available
    
    

    
    Cancer Cell

16. FRESE KK, Simpson KL, Dive C
    Small cell lung cancer enters the era of precision medicine.
    Cancer Cell. 2021 Feb 6. pii: S1535-6108(21)00104.
    PubMed         Abstract available
    
    

    
    Cancer Res

17. PULIDO I, Ollosi S, Aparisi S, Becker JH, et al
    Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
    Cancer Res. 2020;80:4224-4232.
    PubMed         Abstract available
    
    
18. DAGNINO S, Bodinier B, Guida F, Smith-Byrne K, et al
    Prospective identification of elevated circulating CDCP1 in patients years before onset of lung cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-3454.
    PubMed         Abstract available
    
    
19. DAVENPORT ML, Echols JB, Silva AD, Anderson JC, et al
    miR-31 displays subtype specificity in lung cancer.
    Cancer Res. 2021 Feb 8. pii: 0008-5472.CAN-20-2769.
    PubMed         Abstract available
    
    
20. BELLERI M, Paganini G, Coltrini D, Ronca R, et al
    BETA-GALACTOSYLCERAMIDASE PROMOTES MELANOMA GROWTH VIA MODULATION OF CERAMIDE METABOLISM.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-3382.
    PubMed         Abstract available
    
    
21. HARRISON EB, Porrello A, Bowman BM, Belanger AR, et al
    A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking.
    Cancer Res. 2020;80:4972-4985.
    PubMed         Abstract available
    
    
22. SOOTOME H, Fujita H, Ito K, Ochiiwa H, et al
    Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Cancer Res. 2020;80:4986-4997.
    PubMed         Abstract available
    
    
23. MCCLATCHY DM, Willers H, Hata AN, Piotrowska Z, et al
    Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
    Cancer Res. 2020;80:5121-5133.
    PubMed         Abstract available
    
    
24. SU Y, Zhang X, Bidlingmaier S, Behrens CR, et al
    ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen.
    Cancer Res. 2020;80:4552-4564.
    PubMed         Abstract available
    
    
25. SANCHEZ-MAGRANER L, Miles J, Baker CL, Applebee CJ, et al
    High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Cancer Res. 2020;80:4244-4257.
    PubMed         Abstract available
    
    
26. EL-NIKHELY N, Karger A, Sarode P, Singh I, et al
    Metastasis-Associated Protein 2 Represses NF-kappaB to Reduce Lung Tumor Growth and Inflammation.
    Cancer Res. 2020;80:4199-4211.
    PubMed         Abstract available
    
    
27. DAI C, Charlestin V, Wang M, Walker ZT, et al
    Aquaporin-7 Regulates the Response to Cellular Stress in Breast Cancer.
    Cancer Res. 2020 Jul 6. pii: 0008-5472.CAN-19-2269.
    PubMed         Abstract available
    
    

    
    Cancer Sci

28. MA YC, Tian PF, Chen ZP, Yue DS, et al
    Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small cell lung cancer.
    Cancer Sci. 2021 Feb 10. doi: 10.1111/cas.14845.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

29. MASPERO D, Dassano A, Pintarelli G, Noci S, et al
    Read-through transcripts in lung: germline genetic regulation and correlation with the expression of other genes.
    Carcinogenesis. 2020;41:918-926.
    PubMed         Abstract available
    
    

    
    Chest

30. PINSKY PF, Lau YK, Doubeni CA
    Potential Disparities by Sex and Race-ethnicity in Lung Cancer Screening Eligibility Rates.
    Chest. 2021 Feb 2. pii: S0012-3692(21)00232-4. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    
31. ZHOU K, Che G
    The Surgical Approach and Duration of Surgery Should Be Considered in Statistical Models for the Analysis of Postoperative Complications in Patients With Resected Lung Cancer.
    Chest. 2021;159:886-887.
    PubMed        
    
    
32. NISHI SPE, Lowenstein LM, Mendoza TR, Lopez Olivo MA, et al
    Shared Decision Making for Lung Cancer Screening: How Well are we "Sharing"?
    Chest. 2021 Feb 5. pii: S0012-3692(21)00115-X. doi: 10.1016/j.chest.2021.
    PubMed         Abstract available
    
    
33. VERDIAL FC, Madtes DK, Cheng GS, Pipavath S, et al
    Multidisciplinary Team-Based Management of Incidentally Detected Lung Nodules.
    Chest. 2020;157:985-993.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

34. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed         Abstract available
    
    
35. ARBOUR KC, Rizvi H, Plodkowski AJ, Hellmann MD, et al
    Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4023.
    PubMed         Abstract available
    
    
36. HARVEY RD, Bruinooge SS, Chen L, Garrett-Mayer E, et al
    Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
    Clin Cancer Res. 2021 Feb 9. pii: 1078-0432.CCR-20-3857.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

37. CALIMAN E, Petreni P, Brugia M, Antonuzzo L, et al
    In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations".
    Clin Lung Cancer. 2020;21:e363-e365.
    PubMed        
    
    
38. METZENMACHER M, Goetz M, Herold T, Stuschke M, et al
    Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V(600)-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30341.
    PubMed        
    
    
39. LU S, Casarini I, Kato T, Cobo M, et al
    Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Clin Lung Cancer. 2021 Jan 6. pii: S1525-7304(20)30337.
    PubMed         Abstract available
    
    
40. FERRARA MG, Martini M, D'Argento E, Forcella C, et al
    PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021 Feb 5. pii: S1525-7304(20)30351.
    PubMed         Abstract available
    
    
41. PASSARO A, Spitaleri G, de Marinis F
    Reply.
    Clin Lung Cancer. 2020;21:e415-e416.
    PubMed        
    
    

    
    Eur Respir J

42. SCHREUDER A, Jacobs C, Lessmann N, Broeders MJ, et al
    Combining pulmonary and cardiac computed tomography biomarkers for disease-specific risk modelling in lung cancer screening.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03386-2020.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

43. SUURMEIJER AJH, Dickson BC, Swanson D, Zhang L, et al
    A morphologic and molecular reappraisal of myoepithelial tumors of soft tissue, bone, and viscera with EWSR1 and FUS gene rearrangements.
    Genes Chromosomes Cancer. 2020;59:348-356.
    PubMed         Abstract available
    
    

    
    Int J Oncol

44. WANG M, Sun XY, Zhou YC, Zhang KJ, et al
    Suppression of Musashi2 by the small compound largazole exerts inhibitory effects on malignant cells.
    Int J Oncol. 2020;56:1274-1283.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

45. FINAZZI T, Haasbeek CJA, Spoelstra FOB, Palacios MA, et al
    Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2020;107:270-278.
    PubMed         Abstract available
    
    
46. AYOUB Z, Ning MS, Brooks ED, Kang J, et al
    Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;107:261-269.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

47. FENG M, Ye X, Chen B, Zhang J, et al
    Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer.
    J Cancer Res Clin Oncol. 2021 Feb 6. pii: 10.1007/s00432-021-03517.
    PubMed         Abstract available
    
    

    
    J Immunol

48. ZHANG Z, Huang X, Wang E, Huang Y, et al
    Suppression of Mll1-Complex by Stat3/Cebpbeta-Induced miR-21a/21b/181b Maintains the Accumulation, Homeostasis, and Immunosuppressive Function of Polymorphonuclear Myeloid-Derived Suppressor Cells.
    J Immunol. 2020;204:3400-3415.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

49. VEERAMACHANENI NK
    Commentary: Computed tomography screening for lung cancer at large in China: Early cure or definitive overtreatment?
    J Thorac Cardiovasc Surg. 2021 Jan 13. pii: S0022-5223(21)00047.
    PubMed        
    
    
50. AL NATOUR RH, He C, Clark MJ, Welsh R, et al
    The influence of tobacco load versus smoking status on outcomes following lobectomy for lung cancer in a statewide quality collaborative.
    J Thorac Cardiovasc Surg. 2020 Dec 10. pii: S0022-5223(20)33305.
    PubMed         Abstract available
    
    
51. GERACI TC, Ng T
    Commentary: Overreliance of propensity-score matched studies in thoracic surgery.
    J Thorac Cardiovasc Surg. 2021;161:417-418.
    PubMed        
    
    
52. RIPLEY RT
    Commentary: Drawing the target after shooting the arrow: The importance of trial design.
    J Thorac Cardiovasc Surg. 2021;161:443-444.
    PubMed        
    
    
53. CHUDGAR NP, Bott MJ
    Commentary: Minimally invasive sleeve lobectomy: Time to roll up our "sleeves" and learn something new?
    J Thorac Cardiovasc Surg. 2021;161:415-416.
    PubMed        
    
    
54. IMAI T, Weksler B
    Commentary: Open or VATS? Roll up your sleeve.
    J Thorac Cardiovasc Surg. 2021;161:414-415.
    PubMed        
    
    

    
    J Thorac Oncol

55. ILIE M, MaziEres J, Chamorey E, Heeke S, et al
    Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Feb 3. pii: S1556-0864(21)01664.
    PubMed         Abstract available
    
    
56. DAGOGO-JACK I, Moonsamy P, Gainor JF, Lennerz JK, et al
    A Phase II Study of Capmatinib in Patients with MET-Altered Lung Cancer Previously Treated with a MET Inhibitor.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01650.
    PubMed         Abstract available
    
    
57. BARTLETT EC, Silva M, Callister ME, Devaraj A, et al
    False negative results in lung cancer screening - Evidence and Controversies.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01652.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

58. SCHOENFELD AJ, Yu HA
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers-Reply.
    JAMA Oncol. 2020;6:1983.
    PubMed        
    
    
59. QI C, Cui H, Chen D
    Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers.
    JAMA Oncol. 2020;6:1982.
    PubMed        
    
    

    
    Lancet Oncol

60. PASS HI
    SMART: logical radiotherapy and surgery beyond MARS.
    Lancet Oncol. 2021;22:156-157.
    PubMed        
    
    

    
    Lung Cancer

61. ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
    Breath profile as composite biomarkers for lung cancer diagnosis.
    Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
    PubMed         Abstract available
    
    
62. HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
    Lung cancer prediction by Deep Learning to identify benign lung nodules.
    Lung Cancer. 2021;154:1-4.
    PubMed         Abstract available
    
    
63. WANG S, Chen H, Zhong J, Qin H, et al
    Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
    Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.
    PubMed        
    
    
64. GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
    Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
    Lung Cancer. 2021;153:165-170.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

65. SUN T, Zhang W, Li Y, Jin Z, et al
    Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.
    Mol Cancer Ther. 2020;19:802-811.
    PubMed         Abstract available
    
    
66. ZHANG ZZ, Yu WX, Zheng M, Liao XH, et al
    PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
    Mol Cancer Ther. 2020;19:906-919.
    PubMed         Abstract available
    
    

    
    N Engl J Med

67. HORITA N, Fukuda N, Kaneko T
    Atezolizumab for PD-L1-Selected Patients with NSCLC.
    N Engl J Med. 2021;384:583-584.
    PubMed        
    
    
68. PIRCHER A, Heidegger I, Wolf D
    Atezolizumab for PD-L1-Selected Patients with NSCLC.
    N Engl J Med. 2021;384:584.
    PubMed        
    
    
69. HERBST RS, Kuriki H, Spigel DR
    Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply.
    N Engl J Med. 2021;384:584-585.
    PubMed        
    
    

    
    Oncogene

70. KWON OS, Lee H, Kong HJ, Kwon EJ, et al
    Correction to: Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer.
    Oncogene. 2021 Feb 11. pii: 10.1038/s41388-021-01642.
    PubMed        
    
    
71. ZHAO L, Wu X, Zheng J, Dong D, et al
    DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution.
    Oncogene. 2021 Feb 9. pii: 10.1038/s41388-021-01657.
    PubMed         Abstract available
    
    

    
    Oncol Rep

72. DONG S, Men W, Yang S, Xu S, et al
    Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
    Oncol Rep. 2020;43:1437-1450.
    PubMed         Abstract available
    
    

    
    PLoS One

73. MAPANGA W, Norris SA, Chen WC, Blanchard C, et al
    Consensus study on the health system and patient-related barriers for lung cancer management in South Africa.
    PLoS One. 2021;16:e0246716.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

74. HOJ JP, Mayro B, Pendergast AM
    The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis.
    Proc Natl Acad Sci U S A. 2020 Dec 14. pii: 2007991117.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: